Skip to main content
PMC home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1982 Sep;36(3):214–219. doi: 10.1136/jech.36.3.214

Measuring the benefits of screening for open neural tube defects.

J B Henderson
PMCID: PMC1052214  PMID: 6815296

Abstract

Evaluation of the costs and benefits of public sector programmes is necessary to plan the optimum uses for society's resources. Here the benefits of screening for open neural tube defects are examined, and the most appropriate methodological approach to their valuation is discussed in the context of the possible provision by the National Health Service of a routine prenatal screening programme. It is argued that, in measuring the benefits of screening, previous evaluations have adopted an approach that is rather unsatisfactory from the standpoint of economic methodology. An attempt is therefore made here to show the effect that adopting a more appropriate approach would have on the estimated value of the benefit of routine screening. The effect is found to be a substantial increase in its estimated value.

Full text

PDF
214

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carter C. O., David P. A., Laurence K. M. A family study of major central nervous system malformations in South Wales. J Med Genet. 1968 Jun;5(2):81–106. doi: 10.1136/jmg.5.2.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carter C. O., Evans K. Spina bifida and anencephalus in greater London. J Med Genet. 1973 Sep;10(3):209–234. doi: 10.1136/jmg.10.3.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chamberlain J. Human benefits and costs of a national screening programme for neural-tube defects. Lancet. 1978 Dec 16;2(8103):1293–1296. doi: 10.1016/s0140-6736(78)92053-6. [DOI] [PubMed] [Google Scholar]
  4. Evans K., Hickman V., Carter C. O. Handicap and social status of adults with spina bifida cystica. Br J Prev Soc Med. 1974 May;28(2):85–92. doi: 10.1136/jech.28.2.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Farrant W. Stress after amniocentesis for high serum alpha-fetoprotein concentrations. Br Med J. 1980 Aug 9;281(6237):452–452. doi: 10.1136/bmj.281.6237.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hagard S., Carter F. A. Preventing the birth of infants with Down's syndrome: a cost-benefit analysis. Br Med J. 1976 Mar 27;1(6012):753–756. doi: 10.1136/bmj.1.6012.753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hagard S., Carter F., Milne R. G. Screening for spina bifida cystica. A cost-benefit analysis. Br J Prev Soc Med. 1976 Mar;30(1):40–53. doi: 10.1136/jech.30.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harris R. Maternal serum alphafetoprotein in pregnancy and the prevention of birth defect. Br Med J. 1980 May 17;280(6225):1199–1202. doi: 10.1136/bmj.280.6225.1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Laurence K. M. Fetal malformations and abnormalities. Lancet. 1974 Oct 19;2(7886):939–942. doi: 10.1016/s0140-6736(74)91142-8. [DOI] [PubMed] [Google Scholar]
  10. Laurence K. M., James N., Miller M., Campbell H. Increased risk of recurrence of pregnancies complicated by fetal neural tube defects in mothers receiving poor diets, and possible benefit of dietary counselling. Br Med J. 1980 Dec 13;281(6255):1592–1594. doi: 10.1136/bmj.281.6255.1592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Layde P. M., von Allmen S. D., Oakley G. P., Jr Maternal serum alpha-fetoprotein screening: a cost-benefit analysis. Am J Public Health. 1979 Jun;69(6):566–573. doi: 10.2105/ajph.69.6.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Modell B., Ward R. H., Fairweather D. V. Effect of introducing antenatal diagnosis on reproductive behaviour of families at risk for thalassaemia major. Br Med J. 1980 Jun 7;280(6228):1347–1350. doi: 10.1136/bmj.280.6228.1347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mooney G. H. Cost-benefit analysis and medical ethics. J Med Ethics. 1980 Dec;6(4):177–179. doi: 10.1136/jme.6.4.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Morris J., Laurence K. M. The effectiveness of genetic counselling for neural-tube malformations. Dev Med Child Neurol Suppl. 1976;(37):157–163. doi: 10.1111/j.1469-8749.1976.tb04298.x. [DOI] [PubMed] [Google Scholar]
  15. Richards I. D., McIntosh H. T., Sweenie S. A genetic study of anencephaly and spina bifida in Glasgow. Dev Med Child Neurol. 1972 Oct;14(5):626–639. doi: 10.1111/j.1469-8749.1972.tb02645.x. [DOI] [PubMed] [Google Scholar]
  16. Smithells R. W., Sheppard S., Schorah C. J., Seller M. J., Nevin N. C., Harris R., Read A. P., Fielding D. W. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet. 1980 Feb 16;1(8164):339–340. doi: 10.1016/s0140-6736(80)90886-7. [DOI] [PubMed] [Google Scholar]
  17. Walker J. H., Thomas M., Russell I. T. Spina bifida--and the parents. Dev Med Child Neurol. 1971 Aug;13(4):462–476. doi: 10.1111/j.1469-8749.1971.tb03053.x. [DOI] [PubMed] [Google Scholar]
  18. Williams A. The cost-benefit approach. Br Med Bull. 1974 Sep;30(3):252–256. doi: 10.1093/oxfordjournals.bmb.a071211. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES